Shopping Cart
Remove All
Your shopping cart is currently empty
CDK2-IN-51
Catalog No. T214032 Copy Product Info
🥰Excellent
CDK2-IN-51 is a pyrazolopyridine derivative and acts as a CDK2 inhibitor with an IC50 of 23.47 nM. It reduces the expression of DNA replication factors (Polα, MCM7, ORC2, and ORC4) and causes cell cycle arrest before the G1 phase. CDK2-IN-51 does not induce apoptosis and does not significantly affect CDK2 protein expression. This compound is applicable in colorectal cancer research.
CDK2-IN-51
Copy Product Info🥰Excellent
Catalog No. T214032
CDK2-IN-51 is a pyrazolopyridine derivative and acts as a CDK2 inhibitor with an IC50 of 23.47 nM. It reduces the expression of DNA replication factors (Polα, MCM7, ORC2, and ORC4) and causes cell cycle arrest before the G1 phase. CDK2-IN-51 does not induce apoptosis and does not significantly affect CDK2 protein expression. This compound is applicable in colorectal cancer research.
CDK2-IN-51
Cas No. 1443-10-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CDK2-IN-51 is a pyrazolopyridine derivative and acts as a CDK2 inhibitor with an IC50 of 23.47 nM. It reduces the expression of DNA replication factors (Polα, MCM7, ORC2, and ORC4) and causes cell cycle arrest before the G1 phase. CDK2-IN-51 does not induce apoptosis and does not significantly affect CDK2 protein expression. This compound is applicable in colorectal cancer research. |
| Targets&IC50 | CDK2:23.47 nM |
| In vitro | CDK2-IN-51 (compound 6) at concentrations of 10-50 μM for 24-72 hours exhibits significant antiproliferative activity in HCT-116 and HT-29 cells, while showing no cytotoxic effects on NCM-460D cells. At concentrations of 40-50 μM for 48 hours, it induces G1 phase pre-stage arrest in HCT-116 and HT-29 cells without causing S phase arrest. Additionally, at these concentrations and duration, CDK2-IN-51 downregulates CDK2 protein targets involved in DNA replication, such as Polα, MCM7, ORC2, and ORC4, without promoting apoptosis or significantly affecting the expression of CDK2 protein. |
| Molecular Weight | 288.35 |
| Formula | C18H16N4 |
| Cas No. | 1443-10-3 |
| Smiles | N=1C2=NN3C(N=C(C=C3C)C)=C2C(=CC1C)C=4C=CC=CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CDK2-IN-51 | purchase CDK2-IN-51 | CDK2-IN-51 cost | order CDK2-IN-51 | CDK2-IN-51 in vitro | CDK2-IN-51 formula | CDK2-IN-51 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.